Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com

Analysts at StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a note issued to investors on Saturday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also commented on MRNS. Jefferies Financial Group reissued a “hold” rating and issued a $0.50 price objective (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Truist Financial lowered shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. JMP Securities reaffirmed a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. Oppenheimer raised shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target on the stock in a research note on Monday, September 23rd. Finally, EF Hutton Acquisition Co. I raised shares of Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Nine investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of MRNS opened at $0.37 on Friday. The company has a market capitalization of $20.50 million, a P/E ratio of -0.15 and a beta of 1.25. Marinus Pharmaceuticals has a one year low of $0.22 and a one year high of $11.26. The business’s 50 day simple moving average is $0.39 and its 200-day simple moving average is $1.08.

Institutional Trading of Marinus Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Suvretta Capital Management LLC grew its stake in shares of Marinus Pharmaceuticals by 32.8% during the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after purchasing an additional 1,253,901 shares during the period. Franklin Resources Inc. boosted its holdings in Marinus Pharmaceuticals by 34.9% during the third quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock worth $8,483,000 after buying an additional 1,219,871 shares during the last quarter. abrdn plc boosted its holdings in Marinus Pharmaceuticals by 146.1% during the third quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock worth $4,679,000 after buying an additional 1,578,329 shares during the last quarter. GSA Capital Partners LLP grew its position in shares of Marinus Pharmaceuticals by 409.4% during the 3rd quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after buying an additional 817,050 shares during the period. Finally, Acadian Asset Management LLC bought a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter valued at about $813,000. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.